AAAAAA

   
Results: 1-7 |
Results: 7
Liquid chromatographic-tandem mass spectrometric urine assay for a highly metabolized cyclic ureidobenzenesulfonamide: issues concerning assay specificity and quality control preparation
Authors: Fisher, AL DePuy, E Shih, T Stearns, R Lee, Y Gottesdiener, K Flattery, S De Smet, M Keymeulen, B Musson, DG
Citation: Al. Fisher et al., Liquid chromatographic-tandem mass spectrometric urine assay for a highly metabolized cyclic ureidobenzenesulfonamide: issues concerning assay specificity and quality control preparation, J PHARM B, 26(5-6), 2001, pp. 739-752
Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production
Authors: Wight, NJ Gottesdiener, K Garlick, NM Atherton, CT Novak, S Gertz, BJ Calder, NA Cote, J Wong, P Dallob, A Hawkey, CJ
Citation: Nj. Wight et al., Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production, GASTROENTY, 120(4), 2001, pp. 867-873
Single dose methodology to assess the influence of an alpha(1)-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia
Authors: Curtis, SP Eardley, I Boyce, M Larson, P Haesen, R Gottesdiener, K Gertz, BJ
Citation: Sp. Curtis et al., Single dose methodology to assess the influence of an alpha(1)-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia, BR J CL PH, 49(3), 2000, pp. 269-273
A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX (R)), did not alter theantiplatelet effects of low-dose aspirin in healthy volunteers
Authors: Greenberg, HE Gottesdiener, K Huntington, M Wong, P Larson, P Wildonger, L Gillen, L Dorval, E Waldman, SA
Citation: He. Greenberg et al., A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX (R)), did not alter theantiplatelet effects of low-dose aspirin in healthy volunteers, J CLIN PHAR, 40(12), 2000, pp. 1509-1515
Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration
Authors: Dallob, A De Lepeleire, I Van Hecken, A Porras, A Depre, M Mukhopadhyay, S Flynn, M Wildonger, L Gottesdiener, K Tanaka, W De Schepper, P
Citation: A. Dallob et al., Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration, INFLAMM RES, 48, 1999, pp. S130-S131
Efficacy and tolerability of the specific cyclooxygenase-2 inhibitor DFP compared with naproxen sodium in patients with postoperative dental pain
Authors: Gottesdiener, K Mehlisch, DR Huntington, M Yuan, WY Brown, P Gertz, B Mills, S
Citation: K. Gottesdiener et al., Efficacy and tolerability of the specific cyclooxygenase-2 inhibitor DFP compared with naproxen sodium in patients with postoperative dental pain, CLIN THER, 21(8), 1999, pp. 1301-1312
Acute effect of ephedrine on 24-h energy balance
Authors: Shannon, JR Gottesdiener, K Jordan, J Chen, K Flattery, S Larson, PJ Candelore, MR Gertz, B Robertson, D Sun, M
Citation: Jr. Shannon et al., Acute effect of ephedrine on 24-h energy balance, CLIN SCI, 96(5), 1999, pp. 483-491
Risultati: 1-7 |